Evidence map›Paper›PMID 36152139›Full record

ArticleBreast cancer research and treatment2022

Are there differences in outcomes by race among women with metastatic triple-negative breast cancer?

Bridget A Oppong, Angel A Rolle, Amara Ndumele, Yaming Li, James L Fisher, Oindrila Bhattacharyya, Toyin Adeyanju, Electra D Paskett

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Bridget A OppongDepartment of Surgery, The Ohio State University College of Medicine, Columbus, OH, USA. bridget.oppong@osumc.edu.ORCID http://orcid.org/0000-0002-1696-4491
Angel A RolleCentral State University, Wilberforce, OH, USA.
Amara NdumeleWexner College of Medicine, The Ohio State University, Columbus, OH, USA.
Yaming LiDepartment of Surgery, The Ohio State University College of Medicine, Columbus, OH, USA.
James L FisherJames Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH, USA.
Oindrila BhattacharyyaJames Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH, USA.
Toyin AdeyanjuDepartment of Medicine, and Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA.
Electra D PaskettDepartment of Medicine, and Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA.
The Ohio State University · USThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USCentral State University · USThe Ohio State University Wexner Medical Center · US

Funding

Ohio State University P30-CA016058
6 · The paper itself

Abstract

purposeBlack women have higher breast cancer mortality rates than other groups, with Triple-negative breast cancer (TNBC) being more common among AAs with a worse prognosis. Our study seeks to explore differences among Non-Hispanic Black (NHB) vs. White (NHW) women, with Stage IV TNBC, focusing on survival and treatment patterns.

methodsSEER database was queried for TNBC patients diagnosed with metastatic disease from 2012 to 2016. Neighborhood socioeconomic status (nSES) was defined using the Yost index based on income, education, housing, and employment. Univariate and multivariate analyses were performed to evaluate receipt of surgery, radiation, and chemotherapy. Overall survival was evaluated using Kaplan-Meier curve and Cox proportional hazards model analysis.

results25,761 TNBC cases were identified with 1420 being metastatic (5.5%). Bone was the most common site for metastasis, with patients' age being 63.7 years for NHW vs. 59.5 years for NHB. NHB women had the highest percentage of low nSES (62.3% vs 29.3%; p value = 0.001). On univariate analysis, fewer NHBs received radiation compared to NHWs (27.1 vs. 32.6%; p value = 0.040). On multivariate analysis, all women were less likely to undergo treatment if unmarried (p value < 0.01). NHB women had lower median survival compared to NHW women (13 vs. 15 months; p value < 0.01). Receipt of surgery and chemotherapy reduced the risk of mortality (p value < 0.01).

conclusionNHB women had lower median survival with metastatic TNBC. Race was associated with different treatment utilization. With a mortality differential between NHW and NHB women with metastatic TNBC, more investigation is needed to inform strategies to reduce this disparity.

Indexed as

Breast NeoplasmsTriple Negative Breast NeoplasmsBlack PeopleEthnicityFemaleHumansMiddle AgedPrognosisWhite PeopleMetastaticNon-Hispanic BlackNon-Hispanic WhiteSurvivalTNBCTreatment

Identifiers

PMID36152139
OpenAlexW4297175727

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.